secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001104659-24-118342
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet Q3 2024 net loss $14.6M; cash $170M; denifanstat Phase 3 start expected by end of 2024
--------------------------------------------------------------------------------

- Net loss of $14.6M for Q3 2024, vs $6.4M in Q3 2023; R&D expense increased to $12.7M.
- Cash, equivalents and marketable securities of $170.0M as of Sept 30, 2024; expected to fund operations through 2025.
- Denifanstat received FDA Breakthrough Therapy designation for non-cirrhotic MASH (F2/F3 fibrosis); Phase 3 program expected to initiate by end of 2024.
- Phase 2b FASCINATE-2 results published in The Lancet Gastroenterology & Hepatology; end-of-Phase 2 interactions completed.
- License partner Ascletis completed enrollment of 480 patients in Phase 3 acne trial in China; topline results expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924118342/0001104659-24-118342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924118342/tm2428394d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-118342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer